Drug intelligence / Profile preview

AFN005

Development stage
Phase 1
Lead developer
Hefei Afana Biotechnology
Modality
Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intramuscular
01

Overview

AFN005 is an mRNA-based vaccine candidate developed by Hefei Afana Biotechnology for the prevention of respiratory syncytial virus (RSV) infection. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver messenger RNA encoding the RSV fusion (F) protein, which is a key target for neutralizing antibodies. By instructing host cells to produce the F protein, AFN005 stimulates both humoral and cellular immune responses to protect against RSV-related lower respiratory tract disease. It is primarily being developed for use in high-risk populations, including infants and older adults, and represents a significant advancement in the application of mRNA technology beyond COVID-19.

Other names
respiratory syncytial virus mRNA vaccineRSV mRNA vaccine
02

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on AFN005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFN005.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call